Bayer and Zydus cadila yesterday announced and signed to form Joint venture in India named Bayer Zydus Pharma.
Bayer Zydus Pharma will operate in key segments of the Indian pharma market with a focus on: women’s healthcare, diagnostic imaging, cardiovascular diseases, anti-diabetic treatments, and oncology. Bayer Zydus Pharma’s future product portfolio will not only include in-licensed and originator brands, but also patented pharmaceuticals from Bayer HealthCare’s pipeline. The combined portfolio will encompass among others such popular brands as Glucobay®, Xarelto®, Nexavar® and Yaz/Yasmin® from Bayer HealthCare as well as products currently marketed by Zydus Cadila such as Euglim® , Progynova® and Ultravist®.
Note: Yaz/Yasmin patent application rejected in pre grant opposition and Nexavar’s (sorafenib) patent validity is also challenged by Cipla.
Update (17/11/2011): Bayer to bring innovative products into India (link)